Skip to content
logo MSD Oncology Clinical Trials
  • Homepage
  • Trials
    • Main Menu
    • Trial Overview
    • Bladder
    • Breast
    • Colorectal
    • Gastric
    • Gynaecologic
    • Haematological
    • Head and Neck
    • Kidney
    • Liver and Bile Duct
    • Lung
    • Melanoma
    • Oesophageal
    • Paediatric
    • Prostate
    • Solid Tumours
  • About
  • Common Questions
  • For HCPs
  • English (AU)
    • Back
    • English
    • English (AU)
    • Español (LatAm)
    • Français (FR)
    • Português (BR)

Condition: Lymphoma, Non-Hodgkin

This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomised study design in participants with the following haematological malignancies:

  • classical Hodgkin lymphoma (cHL)
  • diffuse large B-cell lymphoma (DLBCL)
  • indolent non-Hodgkin lymphoma (iNHL)

This study will also evaluate the safety and efficacy of pembrolizumab or favezelimab administered as monotherapy in participants with cHL using a 1:1 randomised study design.

The study will have 2 phases: a safety lead-in and an efficacy expansion phase. The recommended Phase 2 dose (RPTD) will be determined in the safety lead-in phase by evaluating dose-limiting toxicities.

There is no primary hypothesis for this study.

Condition: Lymphoma, Non-Hodgkin

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab and Pembrolizumab in Participants With Haematologic Malignancies

March 10, 2022

By Support_Clique

This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) in participants with the following hematological malignancies: classical Hodgkin lymphoma (cHL) diffuse large B-cell lymphoma

logo-white MSD Oncology Clinical Trials
  • MSD Privacy Policy
  • Terms of Use
  • Cookie Preferences
  • Accessibility
  • Contact Us

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.
Merck Sharp & Dohme (Australia) Pty Limited. Level 1 - Building A, 26 Talavera Road, Macquarie Park, NSW 2113
AU-NON-00575 – December 2022

Accessibility

Accessibility